After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Salim Syed’s rating is based on a combination of encouraging developments surrounding Crispr Therapeutics AG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two ...

Jazz Pharmaceuticals JAZZ reported third-quarter 2024 adjusted earnings of $6.61 per share, which beat the Zacks Consensus Estimate of $5.47. Earnings rose 37% year over year. Total revenues rose 9% ...

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc.

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates ...

Robert W. Baird analyst Jack Allen has maintained their neutral stance on CRSP stock, giving a Hold rating yesterday. Jack Allen has given his ...

Global Regenerative Medicine Market is valued at approximately USD 34.56 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 32.4% over the forecast period 2024-2032.